Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
621-640 of 1,694 trials

Crohn’s Disease: MORF-057 Treatment Study

We are testing a new medication, MORF-057, for adults with moderately to severely active Crohn’s disease. The study aims to see if it improves symptoms and endoscopic results compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterologyInternal Medicine

Heart Failure: Balcinrenone/Dapagliflozin Study

We are evaluating a new treatment combining balcinrenone and dapagliflozin for patients with heart failure and kidney problems. The study aims to see if this combination reduces heart-related events and improves health compared to standard treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyNephrology

Roxadustat: Impact on Heart and Metabolism

We are investigating how roxadustat influences glucose and fat metabolism and heart function in participants. This study may help us understand its potential benefits for cardiovascular health.

Risk Factors for Cardiovascular DiseaseMetabolic Syndrome1-2 yearsMonitoring phase (IV)Standard MedicinesCardiologyEndocrinologyInternal Medicine

Hepatocellular Carcinoma: Atezolizumab-Bevacizumab with Bacterial Supplements

We are studying whether adding bacterial supplements to a combination of atezolizumab and bevacizumab helps patients with hepatocellular carcinoma who have not responded to first-line treatment. The trial also looks at the safety of this new approach.

Non-resectable Hepatocellular Carcinoma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib and Defactinib Study

We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.

Recurrent Low-Grade Serous Ovarian Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

MDMA-Assisted Therapy for Treatment-Resistant PTSD

We are studying whether MDMA-assisted therapy can improve symptoms of PTSD in individuals who have not responded to other treatments. This trial also looks at how well this therapy works in a hospital setting.

Posttraumatic Stress Disorder6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

Crohn's Disease: Obefazimod Study

We are testing a new medication, obefazimod, for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The study aims to see if it is more effective and safe compared to a placebo.

Crohn's Disease>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Acute Mesenteric Ischemia: Oral Antibiotics Study

We are investigating whether oral antibiotics can help reduce serious complications in patients with acute mesenteric ischemia. This study compares the effects of antibiotics to a placebo to see if they improve patient outcomes.

Acute Mesenteric Ischemia>2 yearsConfirmation phase (III)Standard MedicinesCardiologyGastroenterology

Psoriatic Arthritis: Tapering Immunosuppressive Therapy

We are studying whether reducing immunosuppressive medication helps adults with psoriatic arthritis maintain stable disease activity. The trial also looks at the safety of this approach.

Psoriatic Arthritis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineRheumatology

Ovarian Cancer: Niraparib Rechallenge Study

We are studying whether Niraparib can help ovarian cancer patients with oligometastatic progression after surgery live longer without their cancer worsening. The trial will also assess safety and various health indicators.

Ovarian Cancer with Oligometastatic Progression1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Liver Transplant: Regulatory T Cell Therapy

We are studying a new treatment using regulatory T cells for liver transplant recipients to see if it is safe and allows them to stop taking tacrolimus. We also want to learn how it affects graft function and patients' quality of life.

Liver TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Advanced Gastric Cancer: AZD0901 Treatment Study

We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.

Advanced Gastric CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Dextroamphetamine for Amphetamine Dependence: A Clinical Trial

We are studying whether daily prescribed dextroamphetamine can help reduce illicit amphetamine use in adults with amphetamine and opioid dependencies. The trial also looks at its effects on mental health, physical health, and overall quality of life.

Comorbid Dependencies to Amphetamines and Opioids6-12 monthsEfficacy phase (II)Standard MedicinesPsychiatry

Ulcerative Colitis: GS-1427 Study

We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Cushing’s Syndrome: Fluasterone Buccal Tablet

We are studying whether fluasterone can help control high blood sugar in adults with Cushing’s syndrome. The trial will also look at its safety and effects on weight and cholesterol levels.

Cushing's Syndrome≤3 monthsEfficacy phase (II)Investigational MedicinesDiabetologyEndocrinologyInternal Medicine

Renal Lifecycle Trial: Dapagliflozin for Severe Chronic Kidney Disease

We are studying whether dapagliflozin can improve kidney and heart health in patients with severe chronic kidney disease. This includes those on dialysis and kidney transplant recipients.

Healthy Participants>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyNephrology

Meningioma Treatment: Everolimus and 177Lu-DOTATATE

We are studying a new combination treatment for patients with grades 2 and 3 refractory meningioma. The goal is to see if this approach can help improve survival and manage tumor growth.

Malignant Meningiomas1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology